Eight children with resistant or relapsed Langerhans' cell histiocytosis (LCH) were given α-interferon (α-IFN) subcutaneously at dosage ranging from 1 to 9 x 10e6 IU/sqm. atalternative days. A patient showed complete response, while seven patients had progression of disease and one died. Therapy related toxicity was slight in four patients, mild in two and life-threatening in two patients. The disappointing results of this study seem to demonstrate no good therapeutical effect of α-IFN in resistant or relapsed LCH patients, confirming some doubt on his wide usefulness as immunotherapy in LCH.
Immunotherapy in recurrent Langerhans' cell histiocytosis (LCH). Experience with α-interferon (α-IFN) and review of literature. Immunoterapia nelle Istiocitosi a cellule di Langerhans ricorrenti. Esperienza con -interferon e revisione della letteratura.
DI CATALDO, Andrea;
1992-01-01
Abstract
Eight children with resistant or relapsed Langerhans' cell histiocytosis (LCH) were given α-interferon (α-IFN) subcutaneously at dosage ranging from 1 to 9 x 10e6 IU/sqm. atalternative days. A patient showed complete response, while seven patients had progression of disease and one died. Therapy related toxicity was slight in four patients, mild in two and life-threatening in two patients. The disappointing results of this study seem to demonstrate no good therapeutical effect of α-IFN in resistant or relapsed LCH patients, confirming some doubt on his wide usefulness as immunotherapy in LCH.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
